On June 2, BaoPharma-B fell 5.3% in regular trading, trading at 21.96 HKD/share, with trading volume of approximately 39.55 million HKD. The decline was primarily driven by systematic weakness across the biotechnology sector, with broad-based selling pressure weighing on individual stocks.

Within the Biotechnology sector, major peers posted significant losses: 3SBIO fell 8.91%, Akeso fell 8.28%, SKB Bio fell 7.4%, Innovent Bio fell 2.66%, and BeiGene fell 1.46%, reflecting widespread risk-off sentiment in the space. BaoPharma-B has been oscillating at depressed levels following a steep 65% plunge in late April. Despite multiple recent positive catalysts — including the appointment of Dr. Liu Yanjun as new chairman, China Post Securities initiating coverage with a Buy rating, and inclusion in the MSCI Global Index — market confidence remains in a fragile recovery phase. Under the backdrop of sector-wide retracement, the stock followed the broader industry lower as investors continued to digest prior volatility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)